Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus immune checkpoint inhibitor for first-line MSI-H/dMMR metastatic or unresectable colorectal cancer
ChiCTR2100051939Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in colorectal cancer (CRC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective response rate. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100051939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051939.